Cinclus Pharma says last Phase III HEEALING1 patient completes treatment
Cinclus Pharma Holding AB (publ) said the last patient in its Phase III HEEALING1 study completed the treatment period. Topline results are expected in Q4 2026.
Cinclus Pharma Holding AB (publ), a clinical pharmaceutical company developing next-generation treatments for acid-related diseases, said the last patient in its Phase III HEEALING1 study will complete the eight-week treatment period today, marking a step toward the Q4 2…